COPD-associated vascular pathology: A future targeting area

Expert Review of Respiratory Medicine

Volumn 2, Issue 3, 2008, Pages 297-299

  Wang, Yaoli ^a   Bai, Chunxue ^a   Wang, Xiangdong ^a,b  

^a FUDAN UNIVERSITY   (China)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR; BIOLOGICAL MARKER; CADMIUM; CHEMOKINE RECEPTOR; GELATINASE A; GELATINASE B; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MATRIX METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; MUSCARINIC RECEPTOR; OXYGEN RADICAL; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHODIESTERASE; PROTEINASE; TUMOR NECROSIS FACTOR ALPHA;

ANGIOGENESIS; CELL STRUCTURE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; DIAGNOSTIC IMAGING; DISEASE ASSOCIATION; EDITORIAL; ENDOTHELIUM CELL; HUMAN; INCIDENCE; INFLAMMATION; LUNG EMPHYSEMA; MACROPHAGE; MONOCYTE; MORBIDITY; MORTALITY; NEUTROPHIL; NUCLEAR MAGNETIC RESONANCE; NUCLEAR MAGNETIC RESONANCE IMAGING; OXIDATIVE STRESS; PATHOGENESIS; POSITRON EMISSION TOMOGRAPHY; PROTEIN TARGETING; SMOOTH MUSCLE FIBER; THROMBOCYTE FUNCTION; TISSUE REGENERATION; VASCULAR DISEASE;

EID: 46949094589     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1586/17476348.2.3.297     Document Type: Editorial

References (24)

1. Walters EH, Reid D, Soltani A, Ward C. Angiogenesis: a potentially critical part of remodelling in chronic airway diseases? Pharmacol. Ther. 118(1), 128-137 (2008).
2. D'Souza AO, Smith MJ, Miller LA, Kavookjian J. An appraisal of pharmacoeconomic evidence of maintenance therapy for COPD. Chest 129(6), 1693-1708 (2006).
3. Villetti G, Bergamaschi M, Bassani F et al. Pharmacological assessment of the duration of action of glycopyrrolate vs tiotropium and ipratropium in guinea-pig and human airways. Br. J. Pharmacol. 148(3), 291-298 (2006).
4. Pak O, Aldashev A, Welsh D, Peacock A. The effects of hypoxia on the cells of the pulmonary vasculature. Eur. Respir. J. 30(2), 364-372 (2007).
5. Calabrese C, Bocchino V, Vatrella A et al. Evidence of angiogenesis in bronchial biopsies of smokers with and without airway obstruction. Respir. Med. 100(8), 1415-1422 (2006).
6. Nichols J. Combination inhaled bronchodilator therapy in the management of chronic obstructive pulmonary disease. Pharmacotherapy 27(3), 447-454 (2007).
7. Richter K, Stenglein S, Mucke M et al. Onset and duration of action of formoterol and tiotropium in patients with moderate to severe COPD. Respiration 73(4), 414-419 (2006).
8. van Noord JA, Aumann JL, Janssens E et al. Effects of tiotropium with and without formoterol on airflow obstruction and testing hyperinflation in patients with COPD. Chest 129(3), 509-517 (2006).
9. Mapel DW, Nelson LS, Lydick E, Soriano J, Yood MU, Davis KJ. Survival among COPD patients using fluticasone/salmeterol in combination versus other inhaled steroids and bronchodilators alone. COPD 4(2), 127-134 (2007).
10. Joppa P, Petrasova D, Stancak B, Tkacova R. Systemic inflammation in patients with COPD and pulmonary hypertension. Chest 130(2), 326-333 (2006).
11. Sin D, Man SFP. Is systemic inflammation responsible for pulmonary hypertension in COPD? Chest 130(2), 310-312 (2006).
12. Zhao H, Zhao Y, Bai CY, Wang XD. Potentials of interorgan signals in the development of pancreatitis-associated acute lung injury and acute respiratory distress syndrome. J. Organ Dysfunction 1, 32-44 (2005).
13. Fitzgerald MF, Fox JC. Emerging trends in the therapy of COPD: novel anti-inflammatory agents in clinical development. Drug Discov. Today 12(11-12), 479-486 (2007).
14. Wright JL, Tai H, Wang R, Wang X, Churg A. Cigarette smoke upregulates pulmonary vascular matrix metalloproteinases via TNF-α signaling. Am. J. Physiol. Lung Cell Mol. Physiol. 292(1), L125-L133 (2007).
15. Perlstein TS, Lee RT. Smoking, metalloproteinases, and vascular disease. Arteriosder. Thromb. Vasc. Biol. 26(2), 250-256 (2006).
16. Churg A, Cosio M, Wright JL. Mechanisms of cigarette smoke-induced COPD: insights from animal models. Am. J. Physiol. Lung Cell. Mol. Physiol. 294(4), L612-L631 (2008).
17. Sun B, Li H, Shakur Y et al. Role of phosphodiesterase type 3A and 3B in regulating platelet and cardiac function using subtype-selective knockout mice. Cell. Signal. 19(8), 1765-1771 (2007).
18. Rennard SI, Fogarty C, Kelsen S et al. The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 175 (9), 926-934 (2007).
19. Bozinovski S, Hutchinson A, Thompson M et al. Serum amyloid a is a biomarker of acute exacerbations of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 177(3), 269-278 (2008).
20. Sverzellati N, Molinari F, Pirronti T et al. New insights on COPD imaging via CT and MRI. Int. J. Chron. Obstruct. Pulmon, Dis. 2(3), 301-312 (2007).
21. Vlahos R, Bozinovski S, Hamilton JA, Anderson GP. Therapeutic potential of treating chronic obstructive pulmonary disease (COPD) by neutralising granulocyte macrophage-colony stimulating factor (GM-CSF). Pharmacol. Ther. 112(1), 106-115 (2006).
22. Peifer C, Wagner G, Laufer S. New approaches to the treatment of inflammatory disorders small molecule inhibitors of p38 MAP kinase. Curr. Top. Med. Chem. 6(2), 113-149 (2006).
23. Zhang J, Shen B, Lin A. Novel strategies for inhibition of the p38 MAPK pathway. Trends Pharmacol. Sci. 28(6), 286-295 (2007).
24. Rommel C, Camps M, Ji H. PI3K δ and PI3K γ: partners in crime in inflammation in rheumatoid arthritis and beyond? Nat. Rev. Immunol. 7(3), 191-201 (2007).